Pfizer says its COVID-19 vaccine works in children as young as five, and that it will now ask regulators in several countries to approve the drug.

Pfizer and its German partner BioNTech studied a lower dose of their two-dose vaccine in more than 22-hundred kindergarten and elementary school-aged kids.

The companies say the dosage had similar or fewer temporary side-effects, such as sore arms, fever or achiness, than teens experience.

(Canadian Press)

Leave a Reply